TNXP (Tonix Pharmaceuticals Holding) Total Equity: $227.14 Mil (As of Mar. 2026)


TNXP Tonix Pharmaceuticals Holding Corp TNXP
41 GF Score
Price $12.34
GF Value $1.75
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Tonix Pharmaceuticals Holding Total Equity?

Tonix Pharmaceuticals Holding TNXP -0.88% 41 Total Equity is $227.14 Mil as of Mar. 2026. GuruFocus rates TNXP with a GF Score™ of 41/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Tonix Pharmaceuticals Holding's total equity for the quarter that ended in Mar. 2026 was $227.14 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Tonix Pharmaceuticals Holding Total Equity Historical Data

* Premium members only.

The historical data trend for Tonix Pharmaceuticals Holding's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding Total Equity Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 218.72 207.18 105.53 139.56 245.15

Tonix Pharmaceuticals Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 180.40 168.00 231.14 245.15 227.14
TNXP
41GF Score
Tonix Pharmaceuticals Holding Corp TNXP
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tonix Pharmaceuticals Holding Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Tonix Pharmaceuticals Holding's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=277.171-32.021
=245.15

Tonix Pharmaceuticals Holding's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=257.912-30.775
=227.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $227.14 Mil mean?
Tonix Pharmaceuticals Holding (TNXP) has a Total Equity of $227.14 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Tonix Pharmaceuticals Holding and its competitors.
Is Tonix Pharmaceuticals Holding's Total Equity too high?
Tonix Pharmaceuticals Holding's current Total Equity is $227.14 Mil. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Total Equity compare to ALEC and IMUX?
Tonix Pharmaceuticals Holding's Total Equity of $227.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Tonix Pharmaceuticals Holding and its competitors. Tonix Pharmaceuticals Holding's current Total Equity is $227.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $12.34 — trading 605.1% above its estimated fair value. The current Total Equity is $227.14 Mil. Tonix Pharmaceuticals Holding's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Total Equity is $227.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of $12.34 is trading 605.1% above its estimated GF Value™ of $1.75. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for TNXP:

  • Total Equity: $227.14 Mil
  • GF Value™: $1.75 vs. price of $12.34 (605.1% above fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tonix Pharmaceuticals Holding Business Description

Other Exchanges TPM0:Germany
Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
41GF Score

Get the complete analysis for TNXP

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.34
Price
$1.75
GF Value